GreenGene F: factor VIII therapy in the spotlight for US hemophilia A patients

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 4:30:12 PM ET. Details in the imprint.

GreenGene F is Green Cross’ recombinant factor VIII concentrate designed for the treatment and prevention of bleeding episodes in patients with hemophilia A. According to GC Biopharma, the product is a plasma and albumin-free third-generation factor VIII manufactured using recombinant DNA technology and viral safety steps, aimed at reducing the risk of pathogen transmission compared with older plasma-derived therapies. For patients and caregivers in the US, GreenGene F is positioned as a prophylactic and on-demand factor replacement option that can be stored and infused at home through specialty distributors serving the American hemophilia community.

What GreenGene F is designed to do

Hemophilia A is a hereditary bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, which leads to spontaneous bleeding in joints and muscles and prolonged bleeding after injuries or surgery. Standard care in many developed markets focuses on factor VIII replacement to raise circulating levels and prevent bleeds, either with on-demand injections when bleeding occurs or with regular prophylactic infusions to maintain protective trough levels over time. GreenGene F falls into this treatment class, providing recombinant factor VIII (octocog alfa) made in cell culture rather than purified from donated human plasma, a distinction that has become important from both safety and supply perspectives in modern hemophilia care.

GC Biopharma describes GreenGene F as a high-purity, freeze-dried powder that is reconstituted with sterile water immediately before intravenous infusion, typically by patients or caregivers trained in self-administration. The company notes that the manufacturing process integrates multiple viral inactivation and removal steps, such as solvent-detergent treatment and nanofiltration, aiming to minimize theoretical risks from enveloped and non-enveloped viruses. While recombinant production already avoids direct reliance on large pools of donated plasma, these additional steps are designed to add layers of safety consistent with global regulatory expectations for recombinant coagulation factors.

In clinical use, factor VIII replacement therapies like GreenGene F are dosed based on the patient’s bodyweight, baseline factor levels, and the clinical situation, for example whether the goal is routine prophylaxis, treatment of spontaneous joint bleeds, or coverage for major surgery. Dosing regimens for recombinant factor VIII are often expressed in international units (IU) per kilogram, with infusion intervals ranging from every other day to three times weekly for standard half-life products; GC Biopharma positions GreenGene F within this conventional standard half-life factor VIII segment rather than the extended half-life category. For many families, this means establishing a regular home-infusion routine to strike a balance between bleed protection and treatment burden, often coordinated with hemophilia treatment centers that oversee dosing plans, inhibitor testing, and long-term joint health monitoring.

GC Biopharma highlights that GreenGene F has obtained marketing authorizations in multiple markets, including approvals in its home market of South Korea and select international territories, and has been distributed globally through regional partners and specialty distributors. In its corporate materials, the company notes a focus on recombinant biopharmaceuticals and vaccines, with GreenGene F cited as a key element of its rare-disease and hematology portfolio alongside other biologics. This positioning aligns the product with the company’s broader strategy of developing biologic therapies for chronic and life-impacting conditions where reliable manufacturing and consistent quality are crucial for patient outcomes.

From a practical user standpoint, GreenGene F is supplied in single-use vials containing labeled doses of factor VIII in IU, typically accompanied by a diluent vial, transfer device, and basic administration supplies, though exact kit components can vary by market and distributor. Before infusion, the lyophilized powder is dissolved in the provided diluent, gently swirled rather than shaken to avoid foaming, and visually inspected to ensure the solution is clear and free of particulate matter, a standard practice for IV biologic drugs. Patients are generally instructed to infuse the solution slowly via a peripheral vein, with infusion time tailored to comfort and clinical guidance, and to document the lot number, dose, and any adverse reactions in treatment logs for review at clinic visits.

Safety information for factor VIII products like GreenGene F typically notes the risk of inhibitor development, where the patient’s immune system forms neutralizing antibodies against factor VIII, making replacement therapy less effective or ineffective. Hemophilia care teams monitor for inhibitors using standardized assays, particularly in previously untreated patients and during the first 50 exposure days to factor VIII products, which is when inhibitor risk is highest. GC Biopharma’s materials emphasize the safety profile and manufacturing controls of GreenGene F, and prescribers are expected to weigh individual patient risk factors, including family history of inhibitors and the presence of high-risk gene mutations, when designing treatment plans.

Pricing for specialty biologics such as recombinant factor VIII can vary significantly across markets and payers, and list prices are often not disclosed in detail by manufacturers. For US patients, coverage typically involves a combination of commercial insurance, Medicaid, or Medicare, supplemented by manufacturer assistance programs and patient advocacy foundations to help manage out-of-pocket costs. While GC Biopharma does not publish a US list price for GreenGene F, the product competes in a therapeutic space where annual treatment costs can reach into six figures for prophylaxis in adults, depending on dose and weight, underscoring the importance of coverage and financial counseling. US availability is usually coordinated through hemophilia treatment centers and specialty pharmacies rather than walk-in retail channels, reflecting the need for tailored dosing and close clinical follow-up.

In GC Biopharma’s portfolio, GreenGene F complements its broader focus on biologics, vaccines, and rare-disease treatments, contributing to the company’s positioning as a specialized biopharmaceutical player rather than a generalist drug maker. The company highlights its work in vaccines and plasma derivatives while increasingly emphasizing recombinant products like GreenGene F as part of a long-term move toward advanced biologic manufacturing platforms. Shares of Green Cross (KR7006280002, ticker 006280) traded at 120,000 KRW on the Korea Exchange on June 11, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.